Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Kappa Opioid Signaling in the Right Central Amygdala Causes Hindpaw Specific Loss of Diffuse Noxious Inhibitory Controls (DNIC) in Experimental Neuropathic Pain.

Phelps CE, Navratilova E, Dickenson AH, Porreca F, Bannister K.

Pain. 2019 Mar 8. doi: 10.1097/j.pain.0000000000001553. [Epub ahead of print]

PMID:
30870321
2.

Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously.

Navratilova E, Porreca F.

Neuron. 2019 Feb 6;101(3):353-355. doi: 10.1016/j.neuron.2019.01.034.

PMID:
30731054
3.

Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain.

Navratilova E, Ji G, Phelps C, Qu C, Hein M, Yakhnitsa V, Neugebauer V, Porreca F.

Pain. 2019 Apr;160(4):824-832. doi: 10.1097/j.pain.0000000000001458.

PMID:
30681985
4.

Shared Mechanisms of Chronic Pain and Emotional-Motivational Problems: From Basic Science to the Clinics.

Becker S, Navratilova E, Nees F, Van Damme S.

Pain Res Manag. 2018 Nov 19;2018:9305026. doi: 10.1155/2018/9305026. eCollection 2018. No abstract available.

5.

Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.

Nation KM, Dodick DW, Navratilova E, Porreca F.

Cephalalgia. 2018 Oct 4:333102418804157. doi: 10.1177/0333102418804157. [Epub ahead of print]

PMID:
30286616
6.

Emotional and Motivational Pain Processing: Current State of Knowledge and Perspectives in Translational Research.

Becker S, Navratilova E, Nees F, Van Damme S.

Pain Res Manag. 2018 Jul 18;2018:5457870. doi: 10.1155/2018/5457870. eCollection 2018. Review.

7.

Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain.

Gomtsian L, Bannister K, Eyde N, Robles D, Dickenson AH, Porreca F, Navratilova E.

Pain. 2018 Dec;159(12):2512-2521. doi: 10.1097/j.pain.0000000000001355.

PMID:
30086115
8.

Detection and Quantification of Carbohydrate-Deficient Transferrin by MALDI-Compatible Protein Chips Prepared by Ambient Ion Soft Landing.

Darebna P, Spicka J, Kucera R, Topolcan O, Navratilova E, Ruzicka V, Volny M, Novak P, Pompach P.

Clin Chem. 2018 Sep;64(9):1319-1326. doi: 10.1373/clinchem.2017.285452. Epub 2018 Jul 12.

PMID:
30002097
9.

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats.

Cowen SL, Phelps CE, Navratilova E, McKinzie DL, Okun A, Husain O, Gleason SD, Witkin JM, Porreca F.

Pain. 2018 Jul;159(7):1403-1412. doi: 10.1097/j.pain.0000000000001226.

PMID:
29578947
10.

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Nation KM, De Felice M, Hernandez PI, Dodick DW, Neugebauer V, Navratilova E, Porreca F.

Pain. 2018 May;159(5):919-928. doi: 10.1097/j.pain.0000000000001167.

PMID:
29369967
11.

Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer.

Watanabe M, Narita M, Hamada Y, Yamashita A, Tamura H, Ikegami D, Kondo T, Shinzato T, Shimizu T, Fukuchi Y, Muto A, Okano H, Yamanaka A, Tawfik VL, Kuzumaki N, Navratilova E, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918756406. doi: 10.1177/1744806918756406. Epub 2018 Jan 22.

12.

Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system.

Watanabe M, Sugiura Y, Sugiyama E, Narita M, Navratilova E, Kondo T, Uchiyama N, Yamanaka A, Kuzumaki N, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918754934. doi: 10.1177/1744806918754934. Epub 2018 Jan 8.

13.

Effect of the preparation of lime putties on their properties.

Navrátilová E, Tihlaříková E, Neděla V, Rovnaníková P, Pavlík J.

Sci Rep. 2017 Dec 8;7(1):17260. doi: 10.1038/s41598-017-17527-3.

14.

Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.

Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, Dickenson AH, Porreca F.

Pain. 2017 Dec;158(12):2386-2395. doi: 10.1097/j.pain.0000000000001040.

15.

Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F.

Cephalalgia. 2017 Jul;37(8):780-794. doi: 10.1177/0333102417702120. Epub 2017 Apr 4.

16.

Reward, motivation, and emotion of pain and its relief.

Porreca F, Navratilova E.

Pain. 2017 Apr;158 Suppl 1:S43-S49. doi: 10.1097/j.pain.0000000000000798. Review. No abstract available.

17.

Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine.

Rice FL, Xie JY, Albrecht PJ, Acker E, Bourgeois J, Navratilova E, Dodick DW, Porreca F.

Cephalalgia. 2017 Dec;37(14):1350-1372. doi: 10.1177/0333102416677051. Epub 2016 Nov 16.

PMID:
27852962
18.

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain.

Okun A, McKinzie DL, Witkin JM, Remeniuk B, Husein O, Gleason SD, Oyarzo J, Navratilova E, McElroy B, Cowen S, Kennedy JD, Porreca F.

Pain. 2016 Dec;157(12):2731-2738.

19.

Positive emotions and brain reward circuits in chronic pain.

Navratilova E, Morimura K, Xie JY, Atcherley CW, Ossipov MH, Porreca F.

J Comp Neurol. 2016 Jun 1;524(8):1646-52. doi: 10.1002/cne.23968. Epub 2016 Feb 3. Review.

20.

Brain Circuits Encoding Reward from Pain Relief.

Navratilova E, Atcherley CW, Porreca F.

Trends Neurosci. 2015 Nov;38(11):741-750. doi: 10.1016/j.tins.2015.09.003. Review.

21.

Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Becerra L, Bishop J, Barmettler G, Xie Y, Navratilova E, Porreca F, Borsook D.

J Neurophysiol. 2016 Jan 1;115(1):208-17. doi: 10.1152/jn.00632.2015. Epub 2015 Oct 21.

22.

Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Nair P, Yamamoto T, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3716-20. doi: 10.1016/j.bmcl.2015.06.030. Epub 2015 Jun 15.

23.

Behavioral and neurochemical analysis of ongoing bone cancer pain in rats.

Remeniuk B, Sukhtankar D, Okun A, Navratilova E, Xie JY, King T, Porreca F.

Pain. 2015 Oct;156(10):1864-73. doi: 10.1097/j.pain.0000000000000218.

24.

Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain.

Navratilova E, Xie JY, Meske D, Qu C, Morimura K, Okun A, Arakawa N, Ossipov M, Fields HL, Porreca F.

J Neurosci. 2015 May 6;35(18):7264-71. doi: 10.1523/JNEUROSCI.3862-14.2015.

25.

Reward and motivation in pain and pain relief.

Navratilova E, Porreca F.

Nat Neurosci. 2014 Oct;17(10):1304-12. doi: 10.1038/nn.3811. Epub 2014 Sep 25. Review.

26.

Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.

Xie JY, Qu C, Patwardhan A, Ossipov MH, Navratilova E, Becerra L, Borsook D, Porreca F.

Pain. 2014 Aug;155(8):1659-66. doi: 10.1016/j.pain.2014.05.018. Epub 2014 May 23.

27.

Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4975-8. doi: 10.1016/j.bmcl.2013.06.065. Epub 2013 Jul 2.

28.

Analogous responses in the nucleus accumbens and cingulate cortex to pain onset (aversion) and offset (relief) in rats and humans.

Becerra L, Navratilova E, Porreca F, Borsook D.

J Neurophysiol. 2013 Sep;110(5):1221-6. doi: 10.1152/jn.00284.2013. Epub 2013 Jun 19.

29.

Evaluation of reward from pain relief.

Navratilova E, Xie JY, King T, Porreca F.

Ann N Y Acad Sci. 2013 Apr;1282:1-11. doi: 10.1111/nyas.12095. Epub 2013 Mar 15. Review.

30.

Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry.

Navratilova E, Xie JY, Okun A, Qu C, Eyde N, Ci S, Ossipov MH, King T, Fields HL, Porreca F.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20709-13. doi: 10.1073/pnas.1214605109. Epub 2012 Nov 26.

31.

Contribution of PKMζ-dependent and independent amplification to components of experimental neuropathic pain.

King T, Qu C, Okun A, Melemedjian OK, Mandell EK, Maskaykina IY, Navratilova E, Dussor GO, Ghosh S, Price TJ, Porreca F.

Pain. 2012 Jun;153(6):1263-73. doi: 10.1016/j.pain.2012.03.006. Epub 2012 Apr 4.

32.

Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.

Yamamoto T, Nair P, Jacobsen NE, Kulkarni V, Davis P, Ma SW, Navratilova E, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ.

J Med Chem. 2010 Aug 12;53(15):5491-501. doi: 10.1021/jm100157m.

33.

Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.

Yamamoto T, Nair P, Jacobsen NE, Vagner J, Kulkarni V, Davis P, Ma SW, Navratilova E, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ.

J Med Chem. 2009 Aug 27;52(16):5164-75. doi: 10.1021/jm900473p.

34.

Plasmon-waveguide resonance studies of ligand binding to integral proteins in membrane fragments derived from bacterial and mammalian cells.

Salamon Z, Fitch J, Cai M, Tumati S, Navratilova E, Tollin G.

Anal Biochem. 2009 Apr 1;387(1):95-101. doi: 10.1016/j.ab.2009.01.019. Epub 2009 Jan 19.

35.

Novel bifunctional peptides as opioid agonists and NK-1 antagonists.

Nair P, Yamamoto T, Kulkarni V, Moye S, Navratilova E, Davis P, Largent T, Ma SW, Yamamura HI, Vanderah T, Lai J, Porreca F, Hruby VJ.

Adv Exp Med Biol. 2009;611:537-8. No abstract available.

36.

The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Yamamoto T, Nair P, Jacobsen NE, Davis P, Ma SW, Navratilova E, Moye S, Lai J, Yamamura HI, Vanderah TW, Porreca F, Hruby VJ.

J Med Chem. 2008 Oct 23;51(20):6334-47. doi: 10.1021/jm800389v. Epub 2008 Sep 27.

37.

Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.

Yue X, Tumati S, Navratilova E, Strop D, St John PA, Vanderah TW, Roeske WR, Yamamura HI, Varga EV.

Eur J Pharmacol. 2008 Apr 28;584(2-3):272-7. doi: 10.1016/j.ejphar.2008.02.013. Epub 2008 Feb 14.

38.

A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Yamamoto T, Nair P, Vagner J, Largent-Milnes T, Davis P, Ma SW, Navratilova E, Moye S, Tumati S, Lai J, Yamamura HI, Vanderah TW, Porreca F, Hruby VJ.

J Med Chem. 2008 Mar 13;51(5):1369-76. doi: 10.1021/jm070332f. Epub 2008 Feb 12.

39.

Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.

Yamamoto T, Nair P, Davis P, Ma SW, Navratilova E, Moye S, Tumati S, Lai J, Vanderah TW, Yamamura HI, Porreca F, Hruby VJ.

J Med Chem. 2007 Jun 14;50(12):2779-86. Epub 2007 May 22.

40.

Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action.

Navratilova E, Waite S, Stropova D, Eaton MC, Alves ID, Hruby VJ, Roeske WR, Yamamura HI, Varga EV.

Mol Pharmacol. 2007 May;71(5):1416-26. Epub 2007 Feb 22.

PMID:
17322005
41.

Morphine promotes phosphorylation of the human delta-opioid receptor at serine 363.

Navratilova E, Eaton MC, Stropova D, Varga EV, Vanderah TW, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Sep 20;519(3):212-4.

PMID:
16135360
42.

Antinociception depends on the presence of G protein gamma2-subunits in brain.

Varga EV, Hosohata K, Borys D, Navratilova E, Nylen A, Vanderah TW, Porreca F, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Jan 31;508(1-3):93-8. Epub 2005 Jan 12.

PMID:
15680258
43.

Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues.

Gu X, Ying J, Min B, Cain JP, Davis P, Willey P, Navratilova E, Yamamura HI, Porreca F, Hruby VJ.

Biopolymers. 2005;80(2-3):151-63.

PMID:
15660379
44.

Agonist-specific regulation of the delta-opioid receptor.

Varga EV, Navratilova E, Stropova D, Jambrosic J, Roeske WR, Yamamura HI.

Life Sci. 2004 Dec 24;76(6):599-612. Review.

PMID:
15567186
45.

Novel design of bicyclic beta-turn dipeptides on solid-phase supports and synthesis of [3.3.0]-Bicyclo([2,3])-leu-enkephalin analogues.

Gu X, Ying J, Agnes RS, Navratilova E, Davis P, Stahl G, Porreca F, Yamamura HI, Hruby VJ.

Org Lett. 2004 Sep 16;6(19):3285-8.

PMID:
15355033
46.

Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides.

Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M, Keyari CM, Yamamura HI, Porreca F, Hruby VJ, Polt R, Bilsky EJ.

J Pharmacol Exp Ther. 2004 Oct;311(1):290-7. Epub 2004 May 27.

PMID:
15166257
47.

Mutation S363A in the human delta-opioid receptor selectively reduces down-regulation by a peptide agonist.

Navratilova E, Varga EV, Stropova D, Jambrosic JC, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2004 Feb 6;485(1-3):341-3.

PMID:
14757159
48.

Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment.

Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, Roeske WR.

Life Sci. 2003 Dec 5;74(2-3):299-311. Review.

PMID:
14607258
49.
50.

Agonist-specific down-regulation of the human delta-opioid receptor.

Okura T, Varga EV, Hosohata Y, Navratilova E, Cowell SM, Rice K, Nagase H, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2003 Jan 10;459(1):9-16.

PMID:
12505529

Supplemental Content

Loading ...
Support Center